Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin Microspheres vs Minocycline in Moderate to Severe Inflammatory Acne
NCT00392223Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azithromycin in acne vulgaris (2 arms), sponsored by Pfizer. Primary endpoints: Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score at 8 weeks and Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score - Per Protocol Population at 8 weeks. Started Oct 2007; status: terminated.
02
Drugs
azithromycin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT00392223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392223.